Length Of Therapy Becomes An Issue In HCV Protease Inhibitor Race
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering-Plough’s Phase II boceprevir data are likely to fuel the debate.
You may also be interested in...
Vertex Braces For HCV Combo Paradigm With ViroChem Buyout
Takeover gives Vertex two clinical-stage polymerase inhibitors, and recalls Gilead’s key Triangle grab.
Vertex Braces For HCV Combo Paradigm With ViroChem Buyout
Takeover gives Vertex two clinical-stage polymerase inhibitors, and recalls Gilead’s key Triangle grab.
Biolex Takes Over OctoPlus’ Phase II HCV Candidate
For upfront and milestone payments of $149 million, Biolex assumes development costs for Locteron, an interferon alfa.